Randomized Allogeneic Azacitidine Study | Aplastic Anemia & MDS International Foundation
Randomized Allogeneic Azacitidine Study

Clinical Trial: NCT00887068

For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:

The goal of this clinical research study is to learn if Vidaza (azacitidine) will help to control the disease in patients with AML, CMML, or MDS after an allogeneic (donor) stem cell transplant. The safety of this drug will also be studied.

Study Date: 
Wed, 04/01/2009 to Sat, 04/01/2017
Bone Marrow Disease(s): 
  • myelodysplastic syndromes (MDS)
Associated Drug(s): 
Drug: Azacitidine 32 mg/m^2 given through a needle under the skin for five consecutive days of each 28 day cycle and the maximum treatment will be 12 cycles. Other Names: 5-Azacitidine 5-aza Vidaza 5-AZC AZA-CR Ladakamycin NSC-102816